In part 3 of this series, board-certified nurse practitioner Lucia Novak, director of Riverside Diabetes Center, gives strategies that may help prevent clinical inertia and improve diabetes management on patient and practitioner levels. For more, visit www.consultant360.com.

Dr David Flanigan from The Ohio State University Wexner Medical Center discusses a new knee device designed to treat osteoarthritis symptoms, how it could potentially help patients prevent or delay knee replacements, and more.

Dr David Flanigan from The Ohio State University Wexner Medical Center discusses a new knee device designed to treat osteoarthritis symptoms, how it could potentially help patients prevent or delay knee replacements, and more.

Dr Daniel Einhorn from the Scripps Whittier Diabetes Institute talks about how the latest diabetes guidelines impacts treatment for patients with comorbid cardiovascular disease.

Dr Daniel Einhorn from the Scripps Whittier Diabetes Institute talks about how the latest diabetes guidelines impacts treatment for patients with comorbid cardiovascular disease.

Dr David Llewellyn from the University of Exeter Medical School answers our questions about his research on dementia misclassification when using brief cognitive assessments.

Dr David Llewellyn from the University of Exeter Medical School answers our questions about his research on dementia misclassification when using brief cognitive assessments.

Dr Molly Jeffery, of the Mayo Clinic in Minnesota, details a practice that may be undermining patients’ decision-making regarding whether or not to visit emergency care, and discusses her research on a potential solution. For more, visit www.consultant360.com.

Dr Molly Jeffery, of the Mayo Clinic in Minnesota, details a practice that may be undermining patients’ decision-making regarding whether or not to visit emergency care, and discusses her research on a potential solution. For more, visit www.consultant360.com.

In part 2 of this series, board-certified nurse practitioner Lucia Novak, director of Riverside Diabetes Center, discusses the benefits of long-acting insulins and barriers that may prevent more widespread implementation of these therapies. For more, visit www.consultant360.com.